IL10 and neoplasm: Butyrate administration significantly decreased the tumor size and levels of the immunosuppressive markers (PD-L1 and IL-10), their regulators (NF-KB and STAT3), and cancer growth factor (VEGF and GDF-15) in cancer tissues (Figure 6d, e).